Dinutuximab Beta at the HUS and the Toulouse Oncopole
DNB
Dinutuximab Beta at the Strasbourg University Hospitals (HUS) and the Toulouse Oncopole: Comparative Analysis of Patient Pathways, Associated Costs and Quality of Life According to Traditional Hospitalization or Hospital at Home (HAD)
1 other identifier
observational
40
1 country
1
Brief Summary
In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 28, 2023
CompletedFirst Submitted
Initial submission to the registry
February 1, 2024
CompletedFirst Posted
Study publicly available on registry
February 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 28, 2024
CompletedFebruary 23, 2024
February 1, 2024
11 months
February 1, 2024
February 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse.
This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.
The period concerned is from January 1, 1998 to December 31, 2023.
Eligibility Criteria
Subjects aged 2 years to 25 years suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.
You may qualify if:
- Subjects aged 2 years to 25 years
- Male or female gender
- Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023.
- Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.
You may not qualify if:
- Patient or parents of the minor having expressed their opposition to participating in the study.
- specific clinical forms of the disease,
- interfering treatments and associated diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service de Pharmacie - Stérilisation - CHU de Strasbourg - France
Strasbourg, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 1, 2024
First Posted
February 23, 2024
Study Start
November 28, 2023
Primary Completion
November 1, 2024
Study Completion
November 28, 2024
Last Updated
February 23, 2024
Record last verified: 2024-02